Background: Mastocytosis is characterized by the accumulation of aberrant mast cells
| INTRODUCTION
Mast cell related diseases such as systemic mastocytosis or mast cell activation syndrome often cause debilitating symptoms mainly due to mast cell (MC)-derived mediators. [1] [2] [3] Currently, these symptoms are treated symptomatically with histamine antagonists, leukotriene antagonists, cromolyn acid and acetylsalicylic acid. 4 However, this regime is often insufficient to reduce symptoms to an acceptable level in the daily life of patients, especially anaphylaxis, gastrointestinal symptoms or flushing can greatly influence the quality of life. 5 Most recent studies on the treatment of mastocytosis focus on the application of tyrosine kinase inhibitors (TKI) in the advanced forms of systemic mastocytosis (SM). These inhibitors mainly act through targeting of the KIT-receptor to inhibit MC growth. 4, 6, 7 Some of these TKI are only effective in MC with wild-type KIT while most patients with mastocytosis harbour the activating D816V KIT mutation. 8 Although newer TKI like midostaurin are also effective in patients with the D816V KIT mutation,its use is often hampered by gastrointestinal adverse effects. 6 Whereas the search for effective therapies for advanced mastocytosis has been going on for years, it is recognized only recently that TKI might also be of benefit in patients with indolent mastocytosis. The indolent subtype has an excellent prognosis regarding survival, but patients regularly experience symptoms caused by the released MC-mediators rather than from actual tissue invasion by MC. Clinical experience with KIT-targeting TKI in indolent systemic mastocytosis is limited. The multi-TKI masitinib was found to diminish MC mediator-related symptoms such as fatigue and pruritus in 8-25% of patients. 9 Next to wellknown mediators such as histamine, leukotrienes and tryptase, MC produce numerous cytokines which are associated with constitutional symptoms in mastocytosis. [10] [11] [12] [13] Therefore, medication that inhibits the release of these MC mediators would be a valuable addition to the, currently limited, therapeutic arsenal for indolent systemic mastocytosis.
Janus kinase (JAK) molecules are involved in the intracellular transduction of signals from multiple receptors, leading to downstream activation of signal transducer and activation of transcription (STAT) molecules and subsequent cellular responses. 14 Of the different JAK-and STAT molecules and signaling pathways currently known, the JAK2-STAT5 pathway is considered the most important for growth and survival of MC. 15 STAT5 also plays a role in IgEmediated MC degranulation, rendering the JAK2-STAT5 pathway an interesting target for the inhibition of MC activation. 16 In support of this, it has previously been shown that the JAK1/JAK2 inhibitor ruxolitinib attenuates ovalbumin-induced passive systemic anaphylaxis in mice, while another study demonstrated that several JAK2-and STAT5-inhibitors were able to inhibit activation of canine mastocytoma cell lines. 17, 18 Furthermore, two recent case studies of patients with systemic mastocytosis reported that MC mediator-related symptoms decreased upon treatment with ruxolitinib. 19, 20 Although these data suggest that JAK2-STAT5 inhibition might effectively reduce the release of MC mediators, basal data on its actual effect on human MC are scarce. The next step towards safe implementation of JAK-STAT inhibitors in the treatment of mastocytosis would be to further explore their exact effects on human MC.
To investigate this, we conducted in vitro studies with ruxolitinib, using two different human mast cell lines and several parameters of MC activation.
| MATERIALS AND METHODS

| Cell culture
Two different human mast cell lines were used: HMC1 and LAD2. HMC1 cells grow independently of stem cell factor (SCF)
as a result of an activating KIT mutation (kindly provided by dr.
Butterfield, Mayo Clinic, Rochester, Minnesota 
| Beta-hexosaminidase release
MC degranulation was measured by β-hexosaminidase assay, as adopted from Rådinger et al. 23 In brief, 2 × | 1413
| Histamine release
For the determination of histamine release, LAD2 cells were used.
The cells were incubated with varying concentrations of ruxolitinib and subsequently stimulated with codeine for 15 minutes, according to the protocol as described above for the β-hexosaminidase assay.
Histamine levels in the supernatant were measured by ELISA (IBL Solutions, Rorsachenberg, Switzerland). 
| Surface membrane CD63 expression
| Cytotoxicity assay
Cytotoxicity of ruxolitinib and pimozide was tested by several meth- CD63 expression is depicted in histograms as mean fluorescent intensity.
| Cytokine production
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| Compound control
Ruxolitinib was not cytotoxic to either HMC1 as LAD2 cells up to a concentration of 50 μmol/L as determined by microscopy, trypane blue exclusion and by LDH release assay for up to 48 hours of incubation. Pimozide was cytotoxic to both cell lines from a concentration of 50 μmol/L and higher as determined by LDH release assay.
The vehicle, DMSO, did not affect degranulation up to a concentration of 5%, as measured by β-hexosaminidase release and CD63
expression (data not shown).
| Degranulation
First, titration of the stimuli was performed to find the optimal dura- 
| Cytokine and chemokine production
HMC1 cells were used for all experiments performed to evaluate cytokine and chemokine production. First, experiments were performed to determine which substance and duration of stimulation was optimal for the induction of IL-6, TNF-α, MCP-1 and IL-13 production in HMC1 cells. This revealed that the optimal stimulation time to induce production of IL-6 and MCP-1 was 24 hours, and that a stimulation time of 6 hours was optimal for TNF-α. This trend was seen regardless of which stimulus was used. A23187 was more potent stimulus for IL-6 and TNF-α production, whereas Substance P was the best stimulus for MCP-1 production (summarized in Figure 2A) . Since the IL-13 production was low, regardless of the stimulus used, this was not further pursued. Codeine did not induce the production of detectable levels of any of the tested cytokines.
Ruxolitinib effectively inhibited the production of IL-6, TNF-α, 
| Pimozide
To determine the contribution of STAT5 to MC degranulation and cytokine production, we investigated the effect of pimozide, a selective STAT5 inhibitor. Pimozide partly inhibited substance P-and codeine-induced degranulation of LAD2 cells in a concentrationdependent manner, however, the obtained decrease in beta-hexosaminidase release was not statistically significant ( Figure 3 ). Pimozide had more potent inhibitory effect on cytokine production by HMC1 cells. The A23187 induced production of IL-6 and TNF-α by HMC1 cells was already significantly reduced at the lowest concentration of pimozide of 5 μmol/L (P: 0.002 and P: 0.029, respectively, Figure 4A , B). Similarly, the substance P-induced MCP-1 production was also inhibited, reaching statistical significance at a concentration of 20 μmol/L (P: 0.002; Figure 4C ). Of note, the spontaneous 
| DISCUSSION
Here, we provide evidence that the JAK1/JAK2 inhibitor ruxolitinib can efficiently inhibit MC degranulation as well as the production of cytokines. Since substance P and codeine are ligands for G-protein coupled receptors (GPCRs), 28, 29 this work implies a link between the JAK2-STAT5 pathway and GPCRs. These stimuli were chosen because it is well-known that codeine can cause MC degranulation, as is confirmed by the fact that many patients with mastocytosis experience MC mediator related symptoms after ingestion of codeine. 30 However, since codeine is an exogenous stimulus, we repeated most experiments with substance P and/or A23187.
In our study, ruxolitinib clearly inhibited MC activity, but its exact intracellular mechanism is not fully elucidated yet. JAK2, and subsequently STAT5, are situated downstream of KIT in MC, 16 and thereby involved in the proliferation and survival of MC. 15 The involvement of the JAK2-STAT5 pathway in MC degranulation is less well-described, although there is some evidence available. The role of STAT5 in IgE-mediated MC degranulation has been investigated by several groups, and it is now accepted that STAT5 is activated downstream of FcεR1. 16, 31, 32 In line with this, previous work has proven that JAK2 is involved in IgE-mediated leukotriene production in mice. 33 Our current data confirm the role of JAK1 and/or JAK2 in MC degranulation and even more so in cytokine and chemokine production. We also found that selective inhibition of STAT5 with pimozide inhibited MC activity, although this did not reach statistical significance for degranulation. Nevertheless, our data support the theory that STAT5 is important for MC activation, although possibly in a lesser extent than JAK2.
Substance P and codeine are ligands to GPCRs. 28, 29 Ruxolitinib and pimozide both effectively blocked MC activation as induced by
The Effect of Ruxolitinib on Cytokine and Chemokine Production by HMC1 Cells. Legend: After establishing the effect of A23187, codeine and substance P on the production of various cytokines and the cytokine MCP-1 (A), experiments were performed with the optimal stimulus for each cytokine. Incubation with ruxolitinib lead to decreased production of IL-6 (B) and TNF-α (C) after stimulation with A23187 for 24 or 6 hours, respectively. The production of MCP-1 after stimulation with substance P for 24 hours was also inhibited (D). *P < 0.05 and # P < 0.01 as compared with positive control. All bars are depicting the mean of 3 repeated experiments with SE these stimuli. These points at a role for JAK2-STAT5 signalling in GPCR-mediated MC activation. Associations between GPCRs and JAK2-STAT5 signalling have been described in other hematopoietic cell types, for instance for the C-C motif chemokine receptor 5 expressed by T-cells and the platelet activating factor receptor expressed by monocytic cells 34, 35 But to our knowledge, our study is
The Effect of Pimozide on Degranulation of LAD2 Cells. Legend: As measured by beta-hexosaminidase release assay, pimozide partly inhibits degranulation of LAD2 in a dose-dependent manner. This effect was similar for stimulation with substance P 5 μmol/L (A) and codeine 40 μg/mL (B). All bars are depicting the mean of 3 repeated experiments with SE F I G U R E 4 The Effect of Pimozide on Cytokine and Chemokine Production by HMC1 Cells. Legend: Incubation with pimozide lead to decreased production of IL-6 (A) and TNF-α (B) after stimulation with A23187 for 24 or 6 hours, respectively. The production of MCP-1 after stimulation with substance P for 24 hours was also inhibited (C). * P < 0.05, and ** P < 0.001 as compared with positive control. All bars are depicting the mean of 3 repeated experiments with SE the first to suggest an association between GPCRs and a JAK-STAT pathway in MC.
The most important signaling pathway downstream of GPCRs involves phosphoinositide 3-kinase (PI3K), which is a versatile tyrosine kinase that can integrate signals from different receptors. [36] [37] [38] There is some evidence for crosstalk between PI3K and STAT5, specifically in neoplastic MC. 39, 40 Possibly, JAK1/JAK2 inhibition by ruxolitinib ultimately interferes with the crosstalk between PI3K and STAT5, although this hypothesis obviously needs further testing.
Ruxolitinib is a rather specific inhibitor of JAK1 and JAK2, yet at high concentrations it is known to inhibit JAK3 as well. 41, 42 The IC 50 of ruxolitinib for JAK3 inhibition was reported to be 438 + 243 nmol/L in an in vitro model for myeloproliferative neoplasms (MPN), which was~150-200 times higher than the IC 50 for JAK1 or JAK2 inhibition. 41 The IC 50 values for ruxolitinib are much higher in MC: they ranged between 1.3 and 10 μmol/L in our study.
These values are comparable to a study that investigated the effect of ruxolitinib on murine MC. 17 Since higher concentrations of ruxolitinib are necessary to inhibit MC activation compared with the inhibition of myeloid progrenitor cells, it cannot be formally excluded that the observed effect of ruxolitinib on MC also involves inhibition of JAK3 activity.
Regardless of any (exogenous) stimuli, neoplastic MC constitutively exhibit high levels of phosphorylated STAT5. 43 Additional evidence for the continuous auto-activation of MC in patients with mastocytosis comes from the elevated levels of MC mediators at random measurements in blood and urine of these patients. 11, 12, 44 The inhibition of the release and/or production of various MC mediators can potentially reduce debilitating symptoms including pruritus, flushing, diarrhea and anaphylaxis, thereby improving the quality of life of these patients. Excessive MC activity also plays a role in many other diseases, including mast cell activation syndrome, chronic spontaneous urticaria, allergies and fibrotic disease. 45, 46 The reduction of MC mediator levels via the inhibition of JAK-STAT signaling might therefore be of therapeutic interest for these diseases as well.
Ruxolitinib is currently only approved for the treatment of the classical myeloproliferative neoplasms (MPN). In patients with MPN, treatment with ruxolitinib leads to a reduction of daily symptoms like abdominal discomfort, pruritus and fatigue. 47, 48 In line with our findings, the COMFORT-II trial showed a decrease in the levels of IL6, TNF-α and VEGF in patients with MPN that were treated with ruxolitinib. 49 Given the increased number and activity of MC in bone marrow of patients with MPN it was hypothesized that ruxolitinib exerted its beneficial effect in MPN by inhibition of MC mediator release/production. 50, 51 This hypothesis is corroborated by our current study that indeed demonstrates an overall inhibiting effect of ruxolitinib on MC activity. In line with this, two recent case studies showed a convincing decrease in MC mediator related symptoms in systemic mastocytosis upon ruxolitinib treatment 19, 20 Based on our data, combined with other available (pre-)clinical evidence as discussed above, JAK1/JAK2-STAT5 inhibition might represent a promising new therapeutic strategy for patients with mastocytosis and many other MC mediator related diseases. Ultimately, randomized clinical trials are necessary.
| CONCLUSION
We have demonstrated that the JAK1/2 inhibitor ruxolitinib effectively attenuates degranulation and cytokine production by human MC. The fact that pimozide also partly inhibited degranulation, and substantially inhibited cytokine production, suggests a role for STAT5 in MC activation. JAK2-STAT5 inhibition thus emerges as a new, highly effective, method to lower MC mediator levels. Ruxolitinib, and JAK-STAT inhibition in general, are interesting therapeutic options to reduce debilitating symptoms in mastocytosis and a wide range of other MC mediator-related diseases such as mast cell activation syndrome, chronic spontaneous urticaria and even fibrotic disease.
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